ArticleThe veterinary quarterly2025
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.
Article in The veterinary quarterly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.Journal of virology · 2026Article
- Egg Yolk Antibodies Elicited by a Novel Multi-Epitope Recombinant Adenovirus Vaccine Against Genotype G2b PEDV Spike Protein Reduce Mortality and Viral Shedding in Passively Immunized Piglets.Pathogens (Basel, Switzerland) · 2026Article
- Development of an automated chemiluminescence immunoassay for detection of IgA antibodies against porcine epidemic diarrhea virus spike.BMC veterinary research · 2026Article
- A Novel Inactivated Vaccine Based on an Emerging PEDV GIIc Variant Provides Cross-Protection Against Heterologous GII Strains.Vaccines · 2026Article
- Swine Enteric Coronaviruses: An Updated Overview of Epidemiology, Diagnosis, Prevention, and Control.Animals : an open access journal from MDPI · 2026Review
- A needle-free intradermal PEDV S protein vaccine elicits protective lactogenic immunity in piglets.Frontiers in cellular and infection microbiology · 2026Article
- Isolation and assessment of characterization of porcine epidemic diarrhea virus GD1 strain from China.Frontiers in veterinary science · 2026Article
- Emergence of a Highly Virulent Porcine Epidemic Diarrhea Virus (PEDV) G2c Subtype in China: Isolation, Genetic and Pathogenic Characterization, and Cross-Neutralizing Antibody Response.Transboundary and emerging diseases · 2026Article
- A Self-Amplifying RNA Lipid Nanoparticle (saRNA-LNP) Vaccine Provides Effective Protection Against Porcine Epidemic Diarrhea.Transboundary and emerging diseases · 2026Article
- Farm animal coronaviruses: the solution is in vaccines.The veterinary quarterly · 2025Review
- Engineering a TGEV S-trimer chimera with PEDV D0-NTD generates potent neutralizing antibodies against both viruses.Journal of virology · 2025Article
- Development of an Indirect ELISA Based on the PEDV S Protein and Evaluation of Its Correlation With Neutralizing Antibody and Immune Protection.Transboundary and emerging diseases · 2025Article
- Effective control of the emerging PEDV G2-c variant with an inactivated autogenous vaccine.Frontiers in veterinary science · 2025Article
- A nanodiamond-formulated plant protein induces robust immunity against porcine epidemic diarrhea virus in piglets.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea virus (PEDV) causes significant global agricultural losses. Despite commercial inactivated and live attenuated vaccines, persistent outbreaks underscore the need for more effective solutions. Here, we isolated a novel Chinese PEDV variant, PEDV ShXXY2-2023, with amino acid substitutions in key neutralizing epitopes (N-terminal domain, receptor-binding domain, and CO-26K equivalent epitope) compared to vaccine strains. An inactivated ShXXY2-2023 vaccine induced higher neutralizing antibodies and superior cross-protection versus commercial vaccines. Vaccinated sows conferred enhanced protection to offspring, improving piglet survival post-challenge. Maternal serum neutralizing antibody titers correlated strongly with piglet survival; titers of 1:377-1:774 at one week prepartum yielded >80% protective efficacy. These findings emphasize neutralizing antibodies' critical role in PEDV prevention and position ShXXY2-2023 as a promising vaccine candidate, with broader implications for coronavirus vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.